Nov. 26, 2018—Ancora Innovation, LLC, the new collaboration between Vanderbilt and Deerfield Management established earlier this year, has completed its inaugural proposal review process and announced two projects selected for funding.
Aug. 7, 2017—Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.
Sep. 30, 2011—Drug-like molecules described by Vanderbilt researchers could lead to Parkinson's treatments with fewer side effects.
Sep. 22, 2011—The discovery of new compounds that work in a fundamentally different way than those in existing schizophrenia medications may allow for more normal function of brain cells involved in schizophrenia.
Sep. 15, 2011—Researchers at Vanderbilt University Medical Center, in collaboration with Seaside Therapeutics in Cambridge, Mass., have achieved a milestone in the development of a potential new treatment for fragile X syndrome, the most common genetic cause of autism.
Mar. 11, 2011—Vanderbilt University Medical Center has established a new Center for Neuroscience Drug Discovery to accelerate research that may lead to new treatments for Parkinson's disease, schizophrenia and other disorders of the brain.
Pain from the Past: A conversation with a psychiatrist and a scientist about post traumatic stress disorder
Mar. 9, 2011—Watch video of Dr. Paul W. Ragan, associate professor of psychiatry, and Carrie Jones, assistant professor of pharmacology, speaking March 3. Post Traumatic Stress Disorder, or PTSD, is a severe anxiety disorder that occurs in people who have experienced physical or psychological trauma. Triggering events can include experiences like military combat, car accidents, or childhood abuse. PTSD is...